---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269529"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:08:08.409590+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# FibroGen receives $6.4M holdback payment from AstraZeneca on China sale

## Summary
- Received $6.4M from AstraZeneca, satisfying $6.0M first holdback plus $0.4M net cash adjustment.
- China operations sale closed Aug 29, 2025; total consideration ~$220M ($85M enterprise + ~$135M net cash).
- $210M paid at closing; $4.0M second holdback for indemnity claims remains, releasable nine months post-close.
- Payment marks release of first post-closing holdback under February 2025 share purchase agreement.

## SEC filing metadata
- accession: 0001193125-25-269529
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312525269529/0001193125-25-269529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312525269529/fgen-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269529
- JSON: https://secwatch.observer/filing/0001193125-25-269529.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.